Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 398, Issue 1-2, Pages 101-113Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2014.09.028
Keywords
Endocrine disrupting chemicals; Bisphenol A; Biomonitoring; Pharmacokinetics; Contamination
Categories
Funding
- NIEHS [ES020952, ES021394]
- UMC [MO-VMFC0018]
Ask authors/readers for more resources
There is extensive evidence that bisphenol A (BPA) is related to a wide range of adverse health effects based on both human and experimental animal studies. However, a number of regulatory agencies have ignored all hazard findings. Reports of high levels of unconjugated (bioactive) serum BPA in dozens of human biomonitoring studies have also been rejected based on the prediction that the findings are due to assay contamination and that virtually all ingested BPA is rapidly converted to inactive metabolites. NIH and industry-sponsored round robin studies have demonstrated that serum BPA can be accurately assayed without contamination, while the FDA lab has acknowledged uncontrolled assay contamination. In reviewing the published BPA biomonitoring data, we find that assay contamination is, in fact, well controlled in most labs, and cannot be used as the basis for discounting evidence that significant and virtually continuous exposure to BPA must be occurring from multiple sources. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available